Exploration of adverse events associated with risdiplam use: Retrospective cases from the US Food and Drug Administration Adverse Event Reporting System (FAERS) database
Sign Up to like & getrecommendations! Published in 2024 at "PLOS ONE"
DOI: 10.1371/journal.pone.0298609
Abstract: Risdiplam is a new drug for treating spinal muscular atrophy (SMA). However, pharmacovigilance analyses are necessary to objectively evaluate its safety—a crucial step in preventing severe adverse events (AEs). Accordingly, the primary objective of the… read more here.
Keywords: adverse events; risdiplam; associated risdiplam; drug ... See more keywords